使用自灭活慢病毒载体(TYF-IL-2Rg)进行 SCID-X1 基因转移
使用自灭活慢病毒载体(TYF-IL-2Rg)进行 X 连锁重症联合免疫缺陷病 (SCID-X1) 基因转移
This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
Important Regulatory Notice:
This trial record is only for global academic information registration on ClinicalTrials.gov. Neither the sponsor Beijing Meikang Jimian Biotechnology Co., Ltd. nor collaborator Shenzhen Geno-Immune Medical Institute has obtained NMPA clinical trial approval or clinical technology filing permission to carry out interventional cell therapy trials in mainland China.
ClinicalTrials.gov registration alone does not represent legal approval by Chinese health and drug regulatory authorities.
X-linked severe combined immunodeficiency (SCID-X1) is a genetic disorder caused by defect in the common cytokine receptor chain, normally on the surface of lymphocytes. Individuals with SCID-X1 lack the normal development of a functional immune system and so have difficulty fighting infections, which may lead to chronic or severe illness and death. X-SCID patients are normally rescued by a bone marrow transplant from a healthy donor. This trial aims to treat SCID-X1 using a self-inactivating lentiviral vector (LV) carrying a functional gene to correct the genetic defect. By direct intravenous (iv) injection of the LV (ivlv-X1) to modify immune cells in the body, this treatment may establish normal healthy immune cells and overcome the immunodeficiency.
The primary objectives are to evaluate the safety of the self-inactivating ivlv-X1-LV, the in vivo gene transfer protocol and the efficacy of immune reconstitution in patients overcoming frequent infections present at the time of treatment, assessment of iv LV gene transfer efficiency, and finally the long-term correction of immunodeficiency.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
学习联系方式
- 姓名:Lung-Ji Chang, Ph.D
- 电话号码:+86 0755-86573763
- 邮箱:c@mkgimi.com
学习地点
-
-
Guangdong
-
Shenzhen、Guangdong、中国、518000
- Shenzhen Geno-immune Medical Institute
-
接触:
- Lung-Ji Chang, PhD
- 电话号码:+86 0755-86573763
- 邮箱:c@mkgimi.com
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Diagnosis of SCID-X1 based on:
- A proven mutation in the common interleukin-2 receptor gamma chain gene as defined by direct sequencing of patient DNA.
- T-cell immune deficiency defined as one or more of the following: CD3+ autologous T cells < 300/ul, or less than 50% of normal value for in vitro mitogen stimulation, or absent proliferation in vitro to antigen stimulation.
-
No available HLA identical related donor.
-
With severe infections, including but not limited to: pneumonitis; protracted diarrhea requiring total parenteral nutrition; infection with herpes viruses or adenovirus; disseminated BCG infection.
-
No cytogenetic abnormalities (medullary karyotype) and no detection of main rearrangements associated with acute leukemia.
-
No prior allogeneic stem cell transplantation.
-
Life expectancy ≥ 3 months.
-
Documented to be negative for HIV infection.
-
Written, informed consent obtained prior to any study-specific procedures.
Exclusion Criteria:
- No available molecular diagnosis confirming SCID-X1.
- Existence of an available HLA-identical related donor.
- Diagnosis of active malignant disease other than EBV-associated lymphoproliferative disease.
- Current treatment with any chemotherapeutic agent (becomes eligible if not on treatment for at least 1 month).
- Patients with evidence of infection with HIV-1 or 2.
- Presence of a medical condition indicating that survival will be less than 4 weeks such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is refractory to medical treatment.
- Current treatment with any immunosuppressive agent, excluding corticosteroids.
- Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Single arm
In vivo LV gene transfer to treat SCID-X1 |
ivlv-X1 LV intravenous injection at a dose of ~1x10e9/kg body weight. |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
总生存期
大体时间:1年
|
1年
|
|
|
感染状态变化
大体时间:1年
|
1年
|
|
|
Overall immune reconstitution
大体时间:1 year
|
T and B cell recovery |
1 year
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Lung-Ji Chang, Ph.D、Shenzhen Geno-Immune Medical Institute
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- GIMI-IRB-17014
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.